Sensorion Aktie [WKN DE: A14SVV / ISIN: FR0012596468]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Sensorion SA

25.05.23		Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions (Businesswire)
11.05.23		Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting (Businesswire)
03.05.23		Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023 (Businesswire)
24.04.23		Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023 (Businesswire)
18.04.23		Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference (Businesswire)
06.04.23		Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program (Businesswire)
31.03.23		Sensorion Appoints Khalil Barrage as Interim Chairman of the Board (Businesswire)
30.03.23		Sensorion Announces the Publication of Its 2022 Annual Financial Report (Businesswire)
16.03.23		Sensorion Reports Full-Year 2022 Financial Results and Business Update (Businesswire)
13.03.23		Sensorion Discloses No Exposure To Silicon Valley Bank Closure (Businesswire)
07.03.23		Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe (Businesswire)
27.02.23		Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer (Businesswire)
21.02.23		Sensorion announces R&D Day focusing on its Gene Therapy programs (Businesswire)
02.02.23		Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting (Businesswire)
31.01.23		Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear (Businesswire)
05.01.23		Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound (Businesswire)
03.01.23		Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (Businesswire)
05.12.22		Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco (Businesswire)
30.11.22		Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration (Businesswire)
07.11.22		Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss (Businesswire)
24.10.22		Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France (Businesswire)
06.10.22		Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022 (Businesswire)
26.09.22		Sensorion to Participate in Various Upcoming Investor Conferences (Businesswire)
22.09.22		Sensorion Reports 2022 First Half Results (Businesswire)
14.09.22		Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation (Businesswire)
12.09.22		Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency (Businesswire)
08.09.22		Sensorion to participate in the Inner Ear Biology Workshop in September 2022 (Businesswire)
07.07.22		Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 (Businesswire)
01.07.22		Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation (Businesswire)
24.06.22		Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022 (Businesswire)
15.06.22		Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022 (Businesswire)
09.06.22		Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022 (Businesswire)
07.06.22		Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation (Businesswire)
01.06.22		Sensorion Publishes Results of Combined General Meeting Resolutions (Businesswire)
12.05.22		Sensorion to Attend the American Society of Gene & Cell Therapy (ASGCT) and Gene Therapy Analytical Development Conferences in May 2022 (Businesswire)
10.05.22		Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 31, 2022 (Businesswire)
28.04.22		Sensorion Announces the Publication of Its 2021 Annual Financial Report (Businesswire)
28.04.22		Sensorion Full-Year 2021 Financial Results and Business Highlights (Businesswire)
21.04.22		Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022 (Businesswire)
15.04.22		Sensorion Publishes Results of Extraordinary General Meeting Resolutions (Businesswire)
12.04.22		Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022 (Businesswire)
25.03.22		Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022 (Businesswire)
24.03.22		Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022 (Businesswire)
18.03.22		Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona (Businesswire)
17.03.22		Sensorion Update on SENS-401 (Businesswire)
10.06.21		Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer (Businesswire)
27.05.21		Sensorion to Attend Two Conferences in June 2021 (Businesswire)
18.05.21		Sensorion Publishes Results of Combined General Meeting Resolutions (Businesswire)
30.04.21		Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021 (Businesswire)
09.04.21		Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Experte schlägt Alarm: Platzt die Tesla-Blase schneller als gedacht?

Bitcoin & Co.: "Dr. Doom" Roubini prognostiziert Krypto-Blase und warnt Anleger

NVIDIA vor Zahlen: Bank of America sieht Mega-Potenzial

Ripple Kurs Prognose: 10 US-Dollar bereits in wenigen Wochen?

Raiffeisen-Aktie sinkt deutlich: Bank Austria und RBI stellen Kunden bis Ende 2025 um

DAX 40-Titel Rheinmetall-Aktie: So viel Gewinn hätte eine Rheinmetall-Investition von vor 10 Jahren eingebracht

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.02.2025 17:57
Kaufwert:	EUR
	Hinzufügen Speichern